{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"14"}]}],"title":"QTcF interval increase < 30 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"}]}],"title":"QTcF interval increase: 30 to < 60 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}]}],"title":"QTcF interval increase >= 60 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"10"}]}],"title":"Maximum QTcF interval < 450 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"10"}]}],"title":"Maximum QTcF interval: 450 to < 480 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"title":"Maximum QTcF interval: 480 to < 500 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}],"title":"Maximum QTcF interval >= 500 msec"}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"description":"Maximum absolute values and increases from baseline were summarized for QTcF interval (time from the beginning of Q wave to the end of T wave corresponding to electrical systole corrected for heart rate using Fridericia's formula). Number of participants with QTcF meeting the following criteria is presented: QTcF interval:\\<450 msec; QTcF interval: 450 to \\<480 msec; QTcF interval: 480 to \\<500 msec; QTcF interval \\>=500 msec; QTcF interval increase from baseline: \\<30 msec; QTcF interval increase from baseline: 30 to \\<60 msec; QTcF interval increase from baseline \\>=60 msec. Arms in the time frame description are defined as: Arm A, Glasdegib +LDAC; Arm B, Glasdegib + Decitabine; Arm C, Glasdegib + Cytarabine/Daunorubicin. End of treatment in the time frame were defined as: maximum of 12 cycles from start of therapy or until disease progression or relapse, participant refusal or unacceptable toxicity occurred, whichever came first.","groups":[{"description":"Included all participants who received oral glasdegib in combination with LDAC in phase 1B portion.","id":"OG000","title":"Phase 1B: Glasdegib + LDAC"},{"description":"Included all participants who received oral glasdegib in combination with decitabine in phase 1B portion.","id":"OG001","title":"Phase 1B: Glasdegib + Decitabine"},{"description":"Included all participants who received oral glasdegib in combination with cytarabine/daunorubicin in phase 1B portion.","id":"OG002","title":"Phase 1B: Glasdegib + Cytarabine/Daunorubicin"}],"paramType":"NUMBER","populationDescription":"QTc analysis set: all participants enrolled in the study having at least 1 ECG assessment after receiving at least 1 dose of glasdegib.","reportingStatus":"POSTED","timeFrame":"1 year","title":"Number of Participants With Corrected QT Interval Using Fridericia's Formula (QTcF) Values Meeting Predefined Criteria at Phase 1B","type":"SECONDARY","unitOfMeasure":"Participants"}